Search results
Results from the WOW.Com Content Network
Olopatadine is an active ingredient in eye drops designed to alleviate allergic conjunctivitis, a condition characterized by itchy, red, and watery eyes. It is intended to serve as a superior alternative to eye drops that contain corticosteroids. By utilizing olopatadine, the goal is to minimize the side effects associated with corticosteroids.
In general, eye drops have been recalled over the past year due to either contamination or a lack of sterility. Both are major issues, Aaron Zimmerman, O.D., a clinical professor at The Ohio State ...
Oxymetazoline, sold under the brand name Afrin among others, is a topical decongestant and vasoconstrictor medication. It is available over-the-counter as a nasal spray to treat nasal congestion and nosebleeds, as eye drops to treat eye redness due to minor irritation, and (in the United States) as a prescription topical cream to treat persistent facial redness due to rosacea in adults.
Eye drops or eyedrops are liquid drops applied directly to the surface of the eye usually in small amounts such as a single drop or a few drops. Eye drops usually contain saline to match the salinity of the eye. Drops containing only saline and sometimes a lubricant are often used as artificial tears to treat dry eyes or simple eye irritation ...
The FDA posting of the recall says Teva’s pulling Clear Eyes, Once Daily, Eye Allergy Itch Relief drops for a failed impurities test. This covers the 715,682 bottles in lot Nos. 114349 ...
Burow's solution is an aqueous solution of aluminium triacetate.It is available in the U.S. as an over-the-counter drug for topical administration, with brand names including Domeboro (Moberg Pharma), Domeboro Otic (ear drops), Star-Otic, and Borofair. [1]
Dermatologists explain the best ingredients to look for in an eye cream to treat fine lines and wrinkles. Here, shop the 14 best drugstore eye creams.
Visine (/ ˌ v aɪ ˈ z iː n /), also known as Vispring, is a brand of eye drops produced by Kenvue. [1] Visine was first introduced in 1958 and was acquired by Pfizer in 1999. [2] [3] In 2006, Johnson & Johnson acquired Visine, along with Pfizer's entire consumer healthcare portfolio. [4]